Product Overview

Current drugs target risk factors but not the root cause of disease progression. The development of effective therapies for NASH requires new understanding of the genetic and biological drivers. We have built a comprehensive clinical omics dataset of several thousand consented participants with the goal to compare higher fibrosis vs low/no fibrosis NASH patients to find novel drug targets as well as biomarkers tied to progression of liver fibrosis.



To learn more, download the datasheet below: